0913 GMT - GSK PLC is among the most mentioned companies across news items over the past six hours, according to Factiva data, after the company reported a first-quarter beat and backed its 2023 guidance, although earnings and sales fell on year. The British pharma giant said that first-quarter sales were hit by lower Covid-19 solutions sales compared with the same quarter of 2022. Operating profit and earnings per share were lower due to the previous year's income benefit from the Gilead settlement and higher sales of Covid-19 treatment Xevudy. GSK's vaccine business beat expectations by 8% and best-selling shingles vaccine Shingrix came in line with consensus, analysts at UBS said in a note. Company consensus is expected to remain unchanged following the results, and shares are expected to react neutrally or slightly positively, UBS said. Dow Jones & Co. owns Factiva. (cecilia.butini@wsj.com)

(END) Dow Jones Newswires

April 26, 2023 05:28 ET (09:28 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Aug 2023 to Sep 2023 Click Here for more GSK Charts.
GSK (NYSE:GSK)
Historical Stock Chart
From Sep 2022 to Sep 2023 Click Here for more GSK Charts.